Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Akari Therapeutics ( (AKTX) ) is now available.
On August 19, 2025, Akari Therapeutics, Plc released an updated investor presentation. This presentation will be utilized by company representatives in various meetings, reflecting the company’s ongoing efforts to engage with stakeholders and provide updated information on its operations.
The most recent analyst rating on (AKTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.
Spark’s Take on AKTX Stock
According to Spark, TipRanks’ AI Analyst, AKTX is a Neutral.
Akari Therapeutics’ stock score of 44 reflects significant challenges due to its current financial instability and lack of revenue. While the technical analysis indicates a neutral trend, the company’s speculative nature due to the absence of traditional valuation metrics underscores the risk. However, the recent positive corporate event with the appointment of a new CEO brings some potential for strategic improvement, slightly offsetting the otherwise high-risk profile.
To see Spark’s full report on AKTX stock, click here.
More about Akari Therapeutics
Average Trading Volume: 26,923
Technical Sentiment Signal: Sell
Current Market Cap: $32.94M
Find detailed analytics on AKTX stock on TipRanks’ Stock Analysis page.